JP2023554119A5 - - Google Patents
Info
- Publication number
- JP2023554119A5 JP2023554119A5 JP2023537488A JP2023537488A JP2023554119A5 JP 2023554119 A5 JP2023554119 A5 JP 2023554119A5 JP 2023537488 A JP2023537488 A JP 2023537488A JP 2023537488 A JP2023537488 A JP 2023537488A JP 2023554119 A5 JP2023554119 A5 JP 2023554119A5
- Authority
- JP
- Japan
- Prior art keywords
- cysteine residue
- amino acid
- disulfide bond
- residue substituent
- substituent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063128601P | 2020-12-21 | 2020-12-21 | |
| US63/128,601 | 2020-12-21 | ||
| PCT/CA2021/051855 WO2022133592A1 (en) | 2020-12-21 | 2021-12-21 | Stabilized tcr constructs and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023554119A JP2023554119A (ja) | 2023-12-26 |
| JP2023554119A5 true JP2023554119A5 (enExample) | 2025-01-06 |
Family
ID=82157307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537488A Pending JP2023554119A (ja) | 2020-12-21 | 2021-12-21 | 安定化されたｔｃｒコンストラクト及び使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240409604A9 (enExample) |
| EP (1) | EP4263593A4 (enExample) |
| JP (1) | JP2023554119A (enExample) |
| KR (1) | KR20230123474A (enExample) |
| CN (1) | CN116648256A (enExample) |
| AU (1) | AU2021408160A1 (enExample) |
| CA (1) | CA3167637A1 (enExample) |
| WO (1) | WO2022133592A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3428194T (lt) | 2017-07-14 | 2021-12-10 | Immatics Biotechnologies Gmbh | Pagerinta dvejopo savitumo polipeptido molekulė |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| WO2025087436A1 (zh) * | 2023-10-27 | 2025-05-01 | 北京可瑞生物科技有限公司 | 基于t细胞受体的多特异性多肽分子及其组合物和用途 |
| TW202542204A (zh) * | 2023-12-29 | 2025-11-01 | 大陸商上海岸邁生物科技有限公司 | 融合蛋白及其用途 |
| CN118108833B (zh) * | 2024-03-12 | 2025-05-02 | 缇纱(合肥)生物技术有限公司 | 引入外源二硫键的tcr恒定区及其产品和应用 |
| WO2025214470A1 (zh) * | 2024-04-12 | 2025-10-16 | 江苏恒瑞医药股份有限公司 | 包含t细胞受体恒定区的蛋白质及其医药用途 |
| WO2025224084A1 (en) | 2024-04-22 | 2025-10-30 | Engimmune Therapeutics Ag | Proteins comprising t cell receptor constant domains |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019003768A (es) * | 2016-10-03 | 2019-06-24 | Juno Therapeutics Inc | Moleculas de enlace especificas de hpv. |
| KR102820804B1 (ko) * | 2017-09-22 | 2025-06-16 | 우시 바이올로직스 아일랜드 리미티드 | 신규한 이중특이적 cd3/cd19 폴리펩티드 복합체 |
| AU2018334886B2 (en) * | 2017-09-22 | 2025-06-26 | WuXi Biologics Ireland Limited | Novel bispecific polypeptide complexes |
| JP2020537515A (ja) * | 2017-10-03 | 2020-12-24 | ジュノー セラピューティクス インコーポレイテッド | Ｈｐｖ特異的結合分子 |
| EP3773908A1 (en) * | 2018-04-05 | 2021-02-17 | Juno Therapeutics, Inc. | T cell receptors and engineered cells expressing same |
| MA52207A (fr) * | 2018-04-05 | 2021-02-17 | Editas Medicine Inc | Lymphocytes t exprimant un récepteur recombinant, polynucléotides et procédés associés |
-
2021
- 2021-12-21 WO PCT/CA2021/051855 patent/WO2022133592A1/en not_active Ceased
- 2021-12-21 US US18/258,057 patent/US20240409604A9/en active Pending
- 2021-12-21 CA CA3167637A patent/CA3167637A1/en active Pending
- 2021-12-21 CN CN202180086149.4A patent/CN116648256A/zh active Pending
- 2021-12-21 JP JP2023537488A patent/JP2023554119A/ja active Pending
- 2021-12-21 EP EP21908193.2A patent/EP4263593A4/en active Pending
- 2021-12-21 AU AU2021408160A patent/AU2021408160A1/en not_active Abandoned
- 2021-12-21 KR KR1020237020556A patent/KR20230123474A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023554119A5 (enExample) | ||
| US20240067757A1 (en) | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS | |
| AU2015357053B2 (en) | Domain-exchanged antibody | |
| JP7847584B2 (ja) | 免疫細胞機能をモジュレートするためのｃｄ８抗原結合分子を有する融合物 | |
| ES3008567T3 (en) | Recombinant antibody molecule and its use for target cell restricted t cell activation | |
| EP2794658B1 (en) | Bispecific antibody molecule | |
| JP7853916B2 (ja) | 免疫複合体 | |
| US5932448A (en) | Bispecific antibody heterodimers | |
| JP2020511949A5 (enExample) | ||
| CN110914308A (zh) | 改进的双特异性多肽分子 | |
| CN112424230A (zh) | 双功能结合多肽 | |
| JPH05500068A (ja) | 可溶性一本鎖ｔ細胞レセプター | |
| WO2022125694A1 (en) | Fusions of interleukin polypeptides with bispecific antigen binding molecules for modulating immune cell function | |
| JP2024537096A (ja) | がんの治療のための代替的なＰＤ１－ＩＬ７ｖイムノコンジュゲート | |
| JP2010512154A (ja) | 修飾Ｆｃドメインを含む多量体Ｆｃ受容体ポリペプチド | |
| US20260098090A1 (en) | Fusions with cd8 antigen binding molecules for treating chronic viral infection | |
| WO2023222035A1 (zh) | 抗tigit抗体与il2的融合蛋白或其变体及其应用 | |
| JP2024526080A (ja) | インターロイキン１５多様体 | |
| KR20220061644A (ko) | Pd-l1 및 il-10의 융합단백질을 유효성분으로 하는 이식거부반응 치료용 약학적 조성물 | |
| RU2025135483A (ru) | Рекомбинантный слитый белок для лечения легочной гипертензии | |
| JP3844519B2 (ja) | 免疫抑制剤 | |
| NZ782268A (en) | Fusion polypeptide comprising fc region of immunoglobulin and gdf15 |